



C A R E
CORONA ACCELERATED R&D IN EUROPE

Inserm



Johnson & Johnson



Tackling Coronavirus Through **Science and Collaboration**

Our **AMBITION**



To **accelerate effective therapies** to COVID-19 patients in Europe and around the world, and generate a **truly transformative treatment regimen**

The **largest European research initiative** addressing the challenges of COVID-19




WHO we are

Our **EXPERTS**




Coalition of Europe's best scientific minds from 38 globally-renowned research-driven organisations together with partners from the USA and China

Combines a focus on rapid emergency response with focus on **long-term preparedness** for future outbreaks




Our **RESEARCH**

Significant INVESTMENT



€75.8 million investment over 5 years with a grant from the IMI and contributions from EFPIA partners, IMI Associated Partners and other organisations

An **effective network** of laboratories, clinical centres, data and knowledge repositories to act as a **coronavirus knowledge hub** in Europe



Knowledge HUB

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101005077. The JU receives support from the European Union's Horizon 2020 research and innovation programme, EFPIA, BILL & MELINDA GATES FOUNDATION, GLOBAL HEALTH DRUG DISCOVERY INSTITUTE and UNIVERSITY OF DUNDEE.



C A R E
CORONA ACCELERATED R&D IN EUROPE

www.imi-care.eu



BILL & MELINDA GATES foundation

